Product Description
Mechanisms of Action: NF-KB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astria Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Muscular Dystrophy, Duchenne
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| An Open-Label Extension Study of Edasalonexent in DMD Patients | P3 |
Terminated |
Muscular Dystrophy, Duchenne |
2020-11-26 |
|
| GalaxyDMD | P3 |
Terminated |
Muscular Dystrophy, Duchenne |
2020-10-26 |
42% |
| PolarisDMD | P3 |
Completed |
Muscular Dystrophy, Duchenne |
2020-09-22 |
|
| POLARIS DMD | P3 |
Completed |
Muscular Dystrophy, Duchenne |
2020-09-22 |